BioSpace News Archive

Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1x1 Meetings

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its commercial and market access teams and completed enrollment in the Phase 2a study of vibegron for irritable bowel syndrome (IBS) pain.

Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights. “We set out in 2016 to become the leading precision oncology company focused on syn

Total Revenues Increase 208.6%; Gross Profit Increases 245.2%; Net Loss Narrowed Significantly Company Completes Accretive Acquisition of Mesa Organics and Drives Value to the Bottom Line Company to Host Conference Call and Webcast Today at 4:30 p.m. ET DENVER--( BUSINESS WIRE )-- Schwazze, formerly operating as Medicine Man Technologies Inc. (OTCQX: SHWZ) (“Schwazze " or “the Company”), today announced financial results for its second

Conference Call to be held Thursday, August 13, 2020 at 5:00 pm EDT

Dow announced that Gaurdie Banister Jr., former president and CEO of Aera Energy LLC, an oil and gas exploration and production company jointly owned by Shell Oil Company and ExxonMobil, has been elected to Dow’s Board of Directors, effective immediately.

Dow has declared a dividend of 70 cents per share, payable September 11, 2020, to shareholders of record on August 31, 2020.

Kadmon Holdings, Inc. (NYSE:KDMN) today announced the appointment of Nancy Miller-Rich to its Board of Directors. Nancy possesses an extensive, decades-long track record of business development and commercialization success in varying roles across globally focused healthcare organizations said Harlan W. Waksal, M.D., President and CEO of Kadmon.

Shineco, Inc. announced that the Company’s common stock will trade on a split-adjusted basis following the implementation of a reverse stock split at the ratio of one-for-nine shares on The Nasdaq Capital Market effective with the open of the market on Monday, August 17, 2020.

SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today provided a business update and reported financial results for the quarter ended June 30, 2020.